Epizyme (EPZM) Lifted to Sell at BidaskClub
BidaskClub upgraded shares of Epizyme (NASDAQ:EPZM) from a strong sell rating to a sell rating in a research report report published on Tuesday.
A number of other analysts have also recently commented on the stock. HC Wainwright reiterated a buy rating on shares of Epizyme in a research note on Monday, August 7th. Cann reiterated a buy rating and issued a $26.00 price target on shares of Epizyme in a research note on Thursday, November 2nd. Zacks Investment Research upgraded shares of Epizyme from a hold rating to a buy rating and set a $20.00 price target for the company in a research note on Monday, October 16th. Jefferies Group began coverage on shares of Epizyme in a research note on Wednesday, September 20th. They issued a buy rating and a $23.00 price target for the company. Finally, Oppenheimer reissued a buy rating and issued a $26.00 price objective on shares of Epizyme in a research report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. Epizyme currently has an average rating of Buy and an average price target of $22.67.
Shares of Epizyme (EPZM) traded up $0.30 on Tuesday, reaching $13.00. 488,700 shares of the company traded hands, compared to its average volume of 575,536. Epizyme has a fifty-two week low of $9.30 and a fifty-two week high of $20.45.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. analysts forecast that Epizyme will post -2.23 EPS for the current fiscal year.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total transaction of $246,600.00. Following the sale, the insider now directly owns 23,123 shares in the company, valued at approximately $380,142.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David M. Mott bought 200,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at $91,500. The disclosure for this purchase can be found here. 25.20% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Teachers Advisors LLC increased its stake in Epizyme by 3.1% during the 1st quarter. Teachers Advisors LLC now owns 69,922 shares of the biopharmaceutical company’s stock valued at $1,199,000 after purchasing an additional 2,093 shares in the last quarter. Legal & General Group Plc boosted its holdings in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 795 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Epizyme by 4.5% during the 1st quarter. Vanguard Group Inc. now owns 3,218,862 shares of the biopharmaceutical company’s stock worth $55,202,000 after acquiring an additional 139,066 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Epizyme by 4.7% during the 1st quarter. Geode Capital Management LLC now owns 337,747 shares of the biopharmaceutical company’s stock worth $5,792,000 after acquiring an additional 15,299 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Epizyme by 61.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 65,194 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 24,807 shares during the last quarter. Hedge funds and other institutional investors own 85.28% of the company’s stock.
WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/epizyme-epzm-lifted-to-sell-at-bidaskclub/1752267.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.